Recently, by using autologous CD19-specific CAR-modified T cells, researchers have achieved complete remission in patients with hematologic malignancies like chronic lymphocytic leukemia (84), acute lymphoblastic leukemia (ALL) (85), diffuse large B-cell lymphoma, and follicular lymphoma (86) who were refractory to immunochemotherapy and transplantation or relapsed after the treatment. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.